Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1764 - A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies


09 Oct 2016


Poster display


David Stenehjem


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


D. Stenehjem, S. Gupta, M. Wade, G. Gilcrease, I. Garrido-Laguna, J.R. Weis, J. Whisenant, S. Sharma

Author affiliations

  • Center For Investigational Therapeutics, Huntsman Cancer Institute, 84112 - Salt Lake City/US


Abstract 1764


Combining chemotherapy with immune checkpoint inhibitors may have additive or synergistic clinical activity. The objective of this phase I study was to assess safety and dose limiting toxicities (DLTs) of combining mFOLFOX6 and pembrolizumab in advanced gastrointestinal (GI) malignancies.


This phase I trial used a 3 + 3 dose escalation design and included patients with advanced GI malignancies for which FOLFOX is indicated. Study treatment consisted of a phased regimen with patients receiving two cycles of mFOLFOX6 every 2 weeks followed by subsequent treatments with mFOLFOX6 plus pembrolizumab (75mg or 200mg) IV every 2 weeks. A DLT was considered if there was at least a possible causal relationship to pembrolizumab or the combination and occurred in weeks 4-6 of treatment (Cycles 3 and 4). Safety measures, disease response and biomarkers were assessed.


Ten patients (6 male) with a median age of 60 years (26-72 years) with advanced colon (7), biliary (1), small intestine (1) and gastric (1) malignancies were enrolled to complete this phase I study cohort. Nine had received prior FOLFOX treatment. Three patients enrolled on the 75 mg dose of pembrolizumab and no DLTs were observed. The next seven patients were dose escalated to 200 mg of pembrolizumab. Of the seven patients treated in the 200 mg cohort, one patient was not evaluable for DLTs due to dose reductions to FOLFOX in the first two cycles. There were no DLTs observed at this dose level. The most common grade 3 or 4 adverse events were neutropenia (40%) and hyponatremia (30%). In the 75mg cohort, one patient was evaluable for disease response and had progressive disease. As of April 19, 2016, the following best overall responses have been observed: 2 (28.6%) partial response, 4 (57.1%) stable disease, and 1 (14.3%) progressive disease. Biomarker assessments will be presented.


The combination of mFOLFOX6 with pembrolizumab (200 mg IV every 2 weeks) has an acceptable safety profile. Further assessment of safety and efficacy is being evaluated in phase II dose-expansion cohorts.

Clinical trial identification

ClinicalTrials.gov NCT02268825; First received: October 15, 2014

Legal entity responsible for the study

University of Utah and the Huntsman Cancer Institute


Merck & Co., Inc


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings